Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent

Riluzole, a benzothiazole sodium channel blocker that received US Food and Drug Administration approval to attenuate neurodegeneration in amyotrophic lateral sclerosis in 1995, was found to be safe and potentially efficacious in a spinal cord injury (SCI) population, as evident in a phase I clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Ashley, Chow, Diana S‐L., Wu, Lei, Teng, Yang (Angela), Sarkar, Mahua, Toups, Elizabeth G., Harrop, James S., Schmitt, Karl M., Johnson, Michele M., Guest, James D., Aarabi, Bizhan, Shaffrey, Christopher I., Boakye, Maxwell, Frankowski, Ralph F., Fehlings, Michael G., Grossman, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457124/
https://www.ncbi.nlm.nih.gov/pubmed/33908635
http://dx.doi.org/10.1002/jcph.1876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457124/
https://www.ncbi.nlm.nih.gov/pubmed/33908635
http://dx.doi.org/10.1002/jcph.1876

Ejemplares similares